GC
MYGN icon

Grace Capital’s Myriad Genetics MYGN Stock Holding History

Grace Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-18,846
Closed -$314K – 93
2016
Q4 		$314K Sell
18,846
-631
-3% -$11.4K 0.14% 72
2016
Q3 		$401K Sell
19,477
-29,241
-60% -$742K 0.18% 66
2016
Q2 		$1.49M Sell
48,718
-15,165
-24% -$527K 0.63% 56
2016
Q1 		$2.39M Sell
63,883
-1,027
-2% -$38.7K 1.07% 49
2015
Q4 		$2.8M Buy
64,910
+3,576
+6% +$151K 1.32% 35
2015
Q3 		$2.06M Hold
61,334
– – 0.85% 57
2015
Q2 		$2.06M Sell
61,334
-159,435
-72% -$5.42M 0.85% 57
2015
Q1 		$7.82M Buy
220,769
+157,773
+250% +$5.65M 1.76% 13
2014
Q4 		$2.15M Buy
+62,996
New +$2.24M 0.52% 71

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Grace Capital's MYGN Position: Q1 2017 in Review

Grace Capital sold out of Myriad Genetics (MYGN) in Q1 2017, closing a stake of 18,846 shares — an estimated $314K sold.

Grace Capital first reported a position in MYGN in Q4 2014 and held it in 9 quarters. The position peaked at $7.82M in Q1 2015. 233 funds tracked by Wall St. Rank hold MYGN as of Q1 2017.

  • Grace Capital reported no remaining Myriad Genetics position as of Q1 2017 after selling out during the quarter.
  • Grace Capital sold 18,846 Myriad Genetics shares in Q1 2017, an estimated $314K.
  • Grace Capital first reported a position in Myriad Genetics in Q4 2014 and held it in 9 quarters.
  • Grace Capital's Myriad Genetics position peaked at $7.82M in Q1 2015.
  • 233 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2017.

Based on Grace Capital's 13F filing for Q1 2017, filed 2 May 2017.